Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

NCT00612430 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Gliosarcoma

Interventions

DRUG: Bevacizumab and Etoposide

Sponsor

Duke University

Collaborators

[object Object]